| P2093 | author name string | Guru Sonpavde | |
| | Amanda R Hathaway | |
| | Mary Katherine Baker | |
| P2860 | cites work | Abiraterone in metastatic prostate cancer without previous chemotherapy | Q24612084 |
| | The genomic complexity of primary human prostate cancer | Q24617949 |
| | Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer | Q24632187 |
| | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 |
| | Recent progress in pharmaceutical therapies for castration-resistant prostate cancer | Q27022567 |
| | AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer | Q27853062 |
| | Integrative clinical genomics of advanced prostate cancer | Q27853170 |
| | Sipuleucel-T immunotherapy for castration-resistant prostate cancer | Q27860648 |
| | Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer | Q29616123 |
| | Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer | Q29616218 |
| | Alpha emitter radium-223 and survival in metastatic prostate cancer | Q29617472 |
| | Increased survival with enzalutamide in prostate cancer after chemotherapy | Q29617511 |
| | Abiraterone and increased survival in metastatic prostate cancer | Q29617512 |
| | Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial | Q29620155 |
| | Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer | Q33408024 |
| | Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer | Q33836330 |
| | Chromosome-wide mapping of DNA methylation patterns in normal and malignant prostate cells reveals pervasive methylation of gene-associated and conserved intergenic sequences | Q33931119 |
| | Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer | Q34217642 |
| | ARN-509: a novel antiandrogen for prostate cancer treatment | Q34248790 |
| | Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer | Q34368408 |
| | A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. | Q34403480 |
| | Enzalutamide in metastatic prostate cancer before chemotherapy | Q34422206 |
| | Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial | Q34426881 |
| | Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer | Q34445286 |
| | EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer | Q34462138 |
| | Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. | Q35063446 |
| | Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer | Q35328550 |
| | Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based th | Q35549709 |
| | Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial | Q35567212 |
| | Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial | Q35572535 |
| | Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer | Q35584698 |
| | Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer | Q35967139 |
| | Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. | Q36058291 |
| | Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis | Q36309725 |
| | DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases | Q36623924 |
| | Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee | Q36815316 |
| | Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study | Q36999978 |
| | Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy | Q37325001 |
| | Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. | Q37590738 |
| | Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide | Q38098972 |
| | Castration-resistant prostate cancer: latest evidence and therapeutic implications | Q38233358 |
| | Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology | Q38326306 |
| | Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents. | Q38905865 |
| | AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studies | Q39013354 |
| | AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo | Q39124868 |
| | Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients | Q39155556 |
| | Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients | Q39160474 |
| | Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial | Q41082307 |
| | Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices | Q41287593 |
| | Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer | Q41354811 |
| | Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial | Q41508304 |
| | Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study | Q41904942 |
| | Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone | Q42125663 |
| | Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). | Q43779982 |
| | Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? | Q44060951 |
| | Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. | Q44187537 |
| | Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study | Q46817220 |
| | Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. | Q51533397 |
| | New agents for prostate cancer | Q55981202 |
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 2775-2787 | |
| P577 | publication date | 2015-09-14 | |
| P1433 | published in | Future Oncology | Q2781597 |
| P1476 | title | Emerging agents for the therapy of advanced prostate cancer | |
| P478 | volume | 11 | |